Evidence map›Paper›PMID 37274393›Full record

ReviewRSC advances2023

Hydroxyapatite-based carriers for tumor targeting therapy.

Gongming Qian, Lingya Xiong, Qing Ye

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Gongming QianCollege of Resource and Environmental Engineering, Wuhan University of Science & Technology Wuhan 430081 China qiangongming@wust.edu.cn.ORCID https://orcid.org/0000-0001-8416-3795
Lingya XiongCollege of Resource and Environmental Engineering, Wuhan University of Science & Technology Wuhan 430081 China qiangongming@wust.edu.cn.ORCID https://orcid.org/0009-0009-2379-4281
Qing YeCollege of Resource and Environmental Engineering, Wuhan University of Science & Technology Wuhan 430081 China qiangongming@wust.edu.cn.
Wuhan University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

At present, targeted drug delivery is regarded as the most effective means of tumor treatment, overcoming the lack of conventional chemotherapeutics that are difficult to reach or enter into cancer cells. Hydroxyapatite (HAP) is the main component of biological hard tissue, which can be regarded as a suitable drug carrier due to its biocompatibility, nontoxicity, biodegradation, and absorbability. This review focuses on the cutting edge of HAP as a drug carrier in targeted drug delivery systems. HAP-based carriers can be obtained by doping, modification, and combination, which benefit to improve the loading efficiency of drugs and the response sensitivity of the microenvironment in the synthesis process. The drug adsorbed or

Identifiers

PMID37274393
PMCPMC10234259
OpenAlexW4379377333

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.